Evidence map›Paper›PMID 27220978›Full record

Trial reportHerz2016

Aspiration thrombectomy and intracoronary tirofiban in ST-segment elevation myocardial infarction : Combination treatment for patients undergoing primary percutaneous coronary intervention.

T Geng, J-G Zhang, Z-Y Song, S-P Dai, Y Luo, Z-S Xu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Herz, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

T GengThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China. cz_gtao@163.com.
J-G ZhangThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China.
Z-Y SongThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China.
S-P DaiThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China.
Y LuoThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China.
Z-S XuThe Second Department of Cangzhou Cardiovascular Institute, No. 16 Xinhua Road, 061000, Cangzhou, Hebei, People's Republic of China.
People's Hospital of Cangzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPrimary percutaneous coronary intervention is the most effective treatment for patients with ST-segment elevation myocardial infarction (STEMI). This study aimed to investigate whether the combination of aspiration thrombectomy with intracoronary tirofiban treatment can result in smaller infarcts and better patient prognosis compared with aspiration thrombectomy alone. PATIENTS AND

methodsIn all, 150 patients with STEMI underwent primary percutaneous coronary intervention. Group A received aspiration thrombectomy and group B received a combination treatment of aspiration thrombectomy with intracoronary tirofiban. The endpoint was major adverse cardiovascular events, including myocardial (re)infarction, cardiovascular death, and target vessel revascularization.

resultsThe clinical characteristics of the groups were not significantly different (p > 0.05). The percentage of patients whose thrombolysis in myocardial infarction (TIMI) myocardial perfusion grades were less than 3 was significantly higher for group B than for group A (13.9 vs. 3.8 %, p = 0.029). The infarct size on cardiac magnetic resonance imaging was significantly different between groups (p = 0.036). At 6 months after the operation, the echocardiography results were better for patients in group B than for those in group A (p = 0.024 and p = 0.016, respectively). The frequency of bleeding complications and major adverse cardiac events of the groups were not significantly different (p > 0.05).

conclusionAspiration thrombectomy with intracoronary tirofiban in patients with STEMI is safe and effective. For cases with a large angiographic thrombus burden, tirofiban did not increase the rate of bleeding complications or major adverse cardiovascular events.

Indexed as

ChinaCombined Modality TherapyFemaleFibrinolytic AgentsHumansMaleMiddle AgedPercutaneous Coronary InterventionPrevalenceRisk FactorsST Elevation Myocardial InfarctionSurvival RateThrombectomyTirofibanTreatment OutcomeTyrosineFibrinolytic AgentsTirofibanTyrosineAspiration thrombectomyIntracoronary tirofibanMyocardial infarctionPercutaneous coronary interventionPlatelet glycoprotein IIb/IIIa receptor antagonist

Identifiers

PMID27220978
OpenAlexW2397512206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.